Tag: genomics
-
Foundation, Biopharm Partner on RNA-Interference Therapy
19 June 2014. Alnylam Pharmaceuticals Inc. in Cambridge, Massachusetts and the Alpha-1 Project in Miami are collaborating on advancing Alnylam’s therapy to treat alpha-1 antitrypsin deficiency, a rare genetic condition responsible for liver disorders and a lung disease similar to chronic obstructive pulmonary disease or COPD. Alpha-1 Project is the for-profit venture division of the…
-
Quest, Sloan Kettering Partner on Solid Tumor Diagnostics
2 June 2014. Quest Diagnostics in Madison, New Jersey and Memorial Sloan Kettering Cancer Center in New York are developing tests to give physicians more precise data on genetic causes of solid tumor cancers, such as breast, prostate, colon, and lung cancer. Financial and intellectual property aspects of the collaboration were not disclosed. In the…
-
Epigenetics Biotech Secures $12.9 Million Early Financing
30 May 2014. Rodin Therapeutics Inc., a biotechnology company in Boston developing therapies based on epigenetics — inherited changes in genetic activity outside of DNA — raised $12.9 million in its first venture funding round. The company is a joint venture of Proteros biostructures GmbH in Munich and Atlas Ventures in Cambridge, Massachusetts. Rodin Therapeutics…
-
Ohio State, Cancer Center Partner on Research Database
28 May 2014. Moffitt Cancer Center in Tampa and Ohio State University’s Comprehensive Cancer Center in Columbus are launching a repository of patient data and tumor samples to speed development of therapies and better match patients to clinical trials. Financial details of the Oncology Research Information Exchange Network or Orien created by the collaboration were…
-
Genetic Blood Transfusion Diagnostic Approved by FDA
23 May 2014. The U.S. Food and Drug Administration approved a molecular diagnostic test to help determine genetic compatibility for blood transfusions, a particular need for people requiring frequent transfusions. The PreciseType HEA Molecular BeadChip Test is made by BioArray Solutions, a subsidiary of Immucor, a developer of diagnostics for transplants and transfusions in Norcross,…
-
Engineered Microbes Created to Clean Biodiesel Waste
21 May 2014. Microbiologists at Michigan State University in East Lansing created a process with two types of genetically-engineered bacteria that work together to clean up the waste water in the production of biodiesel, and generate ethanol as a byproduct. The team led by Michigan State’s Gemma Reguera published its findings online earlier this month…
-
Antibody Developer Secures $40M from Foundation Investors
16 May 2014. Kymab Ltd., a developer of human antibodies from mouse genomes, raised $40 million in its second round of venture investment from the Wellcome Trust, an original backer of the company, and Bill & Melinda Gates Foundation. Kymab, based in Cambridge, U.K., is also collaborating with the Gates Foundation in research on discovery…
-
Partnership to Test Genome-Driven Breast Cancer Therapies
15 May 2014. Researchers at Indiana University’s medical school in Indianapolis and Paradigm, a genomic sequencing company in Ann Arbor, Michigan are enrolling patients in a clinical study testing the ability of genomic sequencing to find optimal treatments for an aggressive type of breast cancer. The study covers women with triple-negative breast cancer, a form…
-
Biopharm Starts Genetic Heart Disease Clinical Database
14 May 2014. MyoKardia Inc., a biopharmaceutical company in South San Francisco, California, began a repository of clinical data on patients with genetic heart disorders. The database, known as Sarcomeric Human Cardiomyopathy Registry, or SHaRe, is a joint project with seven medical centers specializing in these conditions in the U.S., U.K., Netherlands, and Italy. SHaRe aims…
-
Heart Disease in Lab Recreated with Stem Cells, Chip Device
12 May 2014. Medical and engineering researchers from Harvard University and affiliated hospitals created heart tissue with a genetic disorder on a chip-like device in the lab using stem cells. The results point to a new method for personalized lab testing of therapies for cardiac patients with cells derived from their own tissue, as well…